Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Chemomab Therapeutics. The associated price target remains the same with $5.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Okunewitch has given his Buy rating due to a combination of factors, including emerging clinical evidence and a solid financial runway. He notes that recent EASL presentations on nebokitug (CM-101) in primary sclerosing cholangitis highlight statistically significant, dose-dependent reductions in gene expression programs tied to fibrosis, macrophage activation, and immune signaling, thereby reinforcing the drug’s mechanistic validity and supporting a biopsy-free Phase 3 trial design.
Okunewitch also emphasizes AI-driven proteomic findings that define a biomarker signature for likely responders, strengthening the rationale for focusing on patients with moderate to severe disease and enhancing partnering appeal. He further points to data connecting CCL24 inhibition with markers of tissue remodeling in comorbid inflammatory bowel disease, suggesting broader therapeutic relevance, while the company’s cash position, which he expects to fund operations into 1Q27 (excluding Phase 3 costs), underpins his unchanged $5 price target and supports his Buy recommendation.
According to TipRanks, Okunewitch is an analyst with an average return of -4.5% and a 36.30% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Ocugen, Kiora Pharmaceuticals, and Definium Therapeutics.
In another report released on May 15, Oppenheimer also maintained a Buy rating on the stock with a $25.00 price target.